Ser516
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser516  -  MLL (human)

Site Information
VHPPLPIsQsPENES   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4709074

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mass spectrometry ( 1 , 3 ) , mutation of modification site ( 2 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Disease tissue studied:
lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
ATR (human) ( 2 )
Kinases, in vitro:
ATR (human) ( 2 )
Treatments:
hydroxyurea ( 2 )

Downstream Regulation
Effects of modification on MLL:
intracellular localization ( 2 ) , molecular association, regulation ( 2 ) , protein stabilization ( 2 )
Effects of modification on biological processes:
cell cycle regulation ( 2 )
Inhibit interaction with:
SKP2 (human) ( 2 )

References 

1

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

2

Liu H, et al. (2010) Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467, 343-6
20818375   Curated Info

3

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info